(주)모아바이오

AntibodySystem

[Antibodysystem] Research Grade Sutimlimab

Cat-No. DHC43601

AntibodySystem는 Primary Antibody Biosimilar - Research Grade

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.

제품 설명

Research Grade Sutimlimab

제품 번호

DHC43601

제품 특징

Catalog No.

DHC43601

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG4-kappa

Clonality

Monoclonal

Target

C1 esterase, Complement C1s subcomponent, C1S, Complement component 1 subcomponent s

Concentration

3.07 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P09871

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

BIVV009, IPN-009, TNT009, CAS: 2049079-64-1

Clone ID

Sutimlimab

Data Image

SDS-PAGE
SDS PAGE for Sutimlimab
SEC-HPLC
The purity of this product is >95% as determined by SEC-HPLC.

References

Autoimmune hemolytic anemia, PMID: 30504336

Antibodies to watch in 2020, PMID: 31847708

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial, PMID: 30559259

New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1, PMID: 33261023

Novel insights into the treatment of complement-mediated hemolytic anemias, PMID: 31523413

Sutimlimab in Cold Agglutinin Disease, PMID: 33826820

C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro, PMID: 30635392

A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway, PMID: 29737533

Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program, PMID: 32176765

2019 ASH Annual Meeting, PMID: 31859224

Cold agglutinin disease: current challenges and future prospects, PMID: 31114413

How I treat cold agglutinin disease, PMID: 33512410

Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous Pemphigoid, PMID: 31229501

Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features, PMID: 32685889

AntibodySystem의 모든 제품들을 만나 보세요!